Equities

Regent Pacific Group Ltd

Regent Pacific Group Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)0.64
  • Today's Change0.00 / 0.00%
  • Shares traded20.00k
  • 1 Year change-27.27%
  • Beta1.1481
Data delayed at least 15 minutes, as of May 28 2024 08:14 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Regent Pacific Group Ltd, formerly Endurance RP Ltd is an investment holding company principally engaged in biopharma and investment businesses. The Company operates its business through two segments. The Biopharma segment is engaged in the research, development, manufacture, marketing and sale of pharmaceutical products. The Corporate Investment segment is engaged in the investment in listed and unlisted corporate entities. The Company is also engaged in aging research and developing artificial intelligence (AI) models and tool products related to aging research. It offers aging and longevity clocks to the longevity clinics, preventative medicine organizations, health clubs, insurance companies, and aging research institutions.

  • Revenue in HKD (TTM)2.47m
  • Net income in HKD-195.55m
  • Incorporated1991
  • Employees17.00
  • Location
    Regent Pacific Group Ltd8FHenley Building 5 Queen's Road Central Hong KongHKG
  • Phone+852 25146111
  • Fax+852 28104792
  • Websitehttp://www.endurancerp.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Huakang Biomedical Holdings Co Ltd26.54m-6.23m50.55m96.00--0.7687--1.90-0.0149-0.01490.06380.13140.3742.692.57276,480.60-8.78-6.96-10.62-8.0164.4966.27-23.48-20.233.82--0.0429---2.77-3.00-88.03---12.03--
Extrawell Pharmaceutical Holdings Ltd68.62m-154.28m97.99m169.00--0.0942--1.43-0.0776-0.07760.02090.43540.05387.479.89379,132.60-12.004.62-12.504.8847.3651.97-223.0773.993.38-0.05140.09680.00-1.82-3.28-1.0133.99121.54--
Sanai Health Industry Group Co Ltd131.58m20.08m99.38m68.004.710.29295.590.75530.00550.00550.03470.08880.3179188.038.441,935,034.003.482.314.723.6528.7734.8710.956.566.22--0.18810.00-30.6016.04-36.23---75.21--
China Health Group Inc23.09m-62.73m111.48m42.00--1.22--4.83-0.063-0.0630.02320.09180.1438--0.246549,744.10-39.076.84-51.269.5238.3374.98-271.7019.19----0.000.0063.67-18.51-267.82--30.37--
BioSino Bio-technology and Science Inc311.53m-12.55m123.00m537.00--0.5425--0.3948-0.0867-0.08672.151.570.49562.791.46580,125.90-3.30-3.84-8.55-10.1744.0640.17-6.66-6.980.9033--0.3956---22.52-0.9513-243.70---16.58--
Canbridge Pharmaceuticals Inc110.86m-408.26m135.95m100.00------1.23-0.962-0.9620.2612-0.1010.18754.164.091,108,618.00-69.04---154.20--62.37---368.26--0.6132-41.341.39--30.26--21.64------
Regent Pacific Group Ltd2.47m-195.55m146.17m17.00------59.07-0.8686-0.86860.011-0.0530.0218--12.19145,572.00-172.08-50.00-694.26-59.04-----7,901.89-2,685.21--------574.47-44.7231.24---50.60--
Kontafarma China Holdings Ltd809.11m-28.84m195.60m720.00--0.1854.430.2418-0.0052-0.00520.1450.18920.42063.227.031,123,760.00-3.18-1.33-4.22-2.1858.2554.70-7.55-4.121.28-6.190.2392---9.50-17.3266.02------
Modern Chinese Medicine Group Co Ltd370.80m52.59m222.00m191.004.220.43563.750.59870.08770.08770.6180.84940.66815.453.801,941,372.009.4720.7610.7525.8230.2841.0214.1820.117.98206.120.00022.54-13.9114.67-44.440.230396.96--
Wai Yuen Tong Medicine Holdings Limited1.36bn36.42m249.77m1.96k7.330.11681.460.18380.03030.03031.131.900.20140.42422.81700,208.600.8907-0.07331.54-0.119649.0842.524.42-0.4560.56631.490.31960.00-7.558.7581.16---12.06--
Shenzhen Neptunus Intrlng Bi tchnq CoLtd1.13bn29.27m271.84m1.44k9.28--12.450.24130.01750.01750.6714--------780,250.90--3.46--5.1339.4849.141.464.29--109.94--0.007.924.19-55.60-12.89-11.10--
PuraPharm Corp Ltd406.86m-106.08m296.92m662.00--1.94--0.7298-0.2685-0.26851.030.38710.43741.044.19614,590.60-11.40-9.20-34.00-19.7053.2459.44-26.07-19.330.3046-2.280.7349---9.20-11.4111.76---13.68--
Hin Sang Group (Interntnl) Hldng Co Ltd92.79m-35.72m311.16m265.00--1.41--3.35-0.0327-0.03270.0850.2020.15242.299.49366,766.80-5.81-4.06-8.74-5.2655.9561.98-38.14-20.980.1129-1.150.5766---32.42-15.45-315.54---36.30--
Data as of May 28 2024. Currency figures normalised to Regent Pacific Group Ltd's reporting currency: Hong Kong Dollar HKD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.